Literature DB >> 18931630

Differences in factors associated with initial growth, CD4, and viral load responses to ART in HIV-infected children in Kampala, Uganda, and the United Kingdom/Ireland.

Addy Kekitiinwa1, Katherine J Lee, A Sarah Walker, Albert Maganda, Katja Doerholt, Sabrina B Kitaka, Alice Asiimwe, Ali Judd, Philippa Musoke, Diana M Gibb.   

Abstract

BACKGROUND: Few studies have directly compared response to antiretroviral therapy (ART) between children living in well-resourced and resource-limited settings. In resource-limited settings non-HIV contributors could reduce the beneficial effects of ART. We compare predictors of short-term immunological, virological, and growth response to ART in HIV-infected children in the United Kingdom/Ireland and Kampala.
METHODS: We analyzed prospective cohort data from 54 UK/Irish hospitals (the Collaborative HIV Paediatric Study) and Mulago Hospital, Kampala, Uganda. Six- and 12-month responses are described among children initiating combination ART (> or = 3 drugs, > or = 2 classes). Six months post-ART, predictors of viral load (VL) suppression <400 copies/mL, CD4% increases > 10%, and height- and weight-for-age z-score increases > or = +0.5 were investigated using logistic regression.
RESULTS: In all, 582 UK/Irish children (76% black African) were younger than 876 Kampala children at ART initiation (median 5.0 vs 7.6 years), with higher CD4% (14%, 8%), lower VL (172,491 and 346,809 copies/mL), and less stunting (-0.8, -2.8) and wasting (-0.6, -2.8). Post-ART, median 12-month changes in the United Kingdom/Ireland and Kampala in CD4% (+12%, +13%) and weight (+0.4, +0.5) were similar, but growth was less in Kampala (+0.20, +0.06, P < 0.001). Younger children in both cohorts had better immunological, weight, and growth responses (all P < 0.001). However, lower pre-ART CD4% predicted better immunological response in the United Kingdom/Ireland but poorer response in Kampala (heterogeneity P = 0.004). Although 70% children in both cohorts had suppressed < 400 copies/mL at 6 months, adolescents starting ART in the United Kingdom/Ireland had somewhat poorer VL responses than those in Kampala (P = 0.15).
CONCLUSIONS: Overall immunological and virologic ART responses were similar in children in both cohorts. Poorer CD4 recovery in more immunosuppressed Kampala children and blunted growth responses likely reflect higher background malnutrition and infection rates in Uganda, suggesting the need for earlier HIV diagnosis, nutritional support, cotrimoxazole prophylaxis, and ART.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18931630     DOI: 10.1097/QAI.0b013e31818cdef5

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  34 in total

Review 1.  Pharmacokinetic optimization of antiretroviral therapy in children and adolescents.

Authors:  Michael N Neely; Natella Y Rakhmanina
Journal:  Clin Pharmacokinet       Date:  2011-03       Impact factor: 6.447

Review 2.  Perinatally acquired HIV infection in adolescents from sub-Saharan Africa: a review of emerging challenges.

Authors:  Elizabeth D Lowenthal; Sabrina Bakeera-Kitaka; Tafireyi Marukutira; Jennifer Chapman; Kathryn Goldrath; Rashida A Ferrand
Journal:  Lancet Infect Dis       Date:  2014-01-07       Impact factor: 25.071

3.  Growth Recovery Among HIV-infected Children Randomized to Lopinavir/Ritonavir or NNRTI-based Antiretroviral Therapy.

Authors:  Jane Achan; Abel Kakuru; Gloria Ikilezi; Florence Mwangwa; Albert Plenty; Edwin Charlebois; Sera Young; Diane Havlir; Moses Kamya; Theodore Ruel
Journal:  Pediatr Infect Dis J       Date:  2016-12       Impact factor: 2.129

4.  Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, open-label trial.

Authors:  Thanyawee Puthanakit; Vonthanak Saphonn; Jintanat Ananworanich; Pope Kosalaraksa; Rawiwan Hansudewechakul; Ung Vibol; Stephen J Kerr; Suparat Kanjanavanit; Chaiwat Ngampiyaskul; Jurai Wongsawat; Wicharn Luesomboon; Nicole Ngo-Giang-Huong; Kea Chettra; Theshinee Cheunyam; Tulathip Suwarnlerk; Sasiwimol Ubolyam; William T Shearer; Robert Paul; Lynne M Mofenson; Lawrence Fox; Matthew G Law; David A Cooper; Praphan Phanuphak; Mean Chhi Vun; Kiat Ruxrungtham
Journal:  Lancet Infect Dis       Date:  2012-10-09       Impact factor: 25.071

Review 5.  Pharmacotherapy of pediatric HIV infection.

Authors:  Natella Rakhmanina; B Ryan Phelps
Journal:  Pediatr Clin North Am       Date:  2012-08-22       Impact factor: 3.278

6.  The long-term effectiveness of generic adult fixed-dose combination antiretroviral therapy for HIV-infected Ugandan children.

Authors:  L N Barlow-Mosha; D S Bagenda; P K Mudiope; M C Mubiru; L M Butler; M G Fowler; P M Musoke
Journal:  Afr Health Sci       Date:  2012-09       Impact factor: 0.927

7.  Adolescent HIV--cause for concern in Southern Africa.

Authors:  Glenda E Gray
Journal:  PLoS Med       Date:  2010-02-02       Impact factor: 11.069

8.  Growth, immune and viral responses in HIV infected African children receiving highly active antiretroviral therapy: a prospective cohort study.

Authors:  Philippa M Musoke; Peter Mudiope; Linda N Barlow-Mosha; Patrick Ajuna; Danstan Bagenda; Michael M Mubiru; Thorkild Tylleskar; Mary G Fowler
Journal:  BMC Pediatr       Date:  2010-08-06       Impact factor: 2.125

9.  Causes of acute hospitalization in adolescence: burden and spectrum of HIV-related morbidity in a country with an early-onset and severe HIV epidemic: a prospective survey.

Authors:  Rashida A Ferrand; Tsitsi Bandason; Praise Musvaire; Natasha Larke; Kusum Nathoo; Hilda Mujuru; Chiratidzo E Ndhlovu; Shungu Munyati; Frances M Cowan; Diana M Gibb; Elizabeth L Corbett
Journal:  PLoS Med       Date:  2010-02-02       Impact factor: 11.069

10.  Causes of morbidity among HIV-infected children on antiretroviral therapy in primary care facilities in Lusaka, Zambia.

Authors:  Mwangelwa Mubiana-Mbewe; Carolyn Bolton-Moore; Yolan Banda; Namwinga Chintu; Mutinta Nalubamba-Phiri; Mark Giganti; M Brad Guffey; Pauline Sambo; Elizabeth M Stringer; Jeffrey S A Stringer; Benjamin H Chi
Journal:  Trop Med Int Health       Date:  2009-08-25       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.